Melanotan-1 (MT-1) Price Comparison — Compare 18 Vendors

View full research →
Melanocortin / photoprotection researchSafety Rating 8/10

Price Comparison

Compare vendors · per 10mg

18 vendors competing

VendorPrice$ / mgUpdated
Ascension Peptides8.5/10$20.00$40.00−50% · code peptidepri$2.00Apr 16, 2026Buy →
Amino Club10/10$23.99$29.99−20% · code PEPTIDEPRICES$2.40May 14, 2026Buy →
Peptyx Labs8.5/10$24.00$30.00−20% · code PEPTIDEPRICES25$2.40May 26, 2026Buy →
Axiom Peptides4/10$25.00$2.50Apr 14, 2026Buy →
Puratek Peptides9.5/10$25.16$27.95−10% · code PEPTIDEPRICES$2.52May 19, 2026Buy →
CertaPeptides7.5/10Out of stock$28.70$31.89−10% · code PEPTIDEPRICES$2.87Jun 27, 2026Buy →

Research details

Melanotan-1 — research data

Research-literature reference data, NOT patient instructions. Not for human use. Consult a licensed clinician for any human application.

Research dose range16 mg SC implant every 2 monthssource ↗
AdministrationSubcutaneous implant (superior iliac crest)
Half-lifeReleased over ~2 days from implant
Safety8/10 · FDA-approved (Scenesse)
NCAA D1Not listed

Overview

About Melanotan-1

Mechanism of action

Non-selective melanocortin receptor agonist (MC1R preference); stimulates eumelanin production in melanocytes; photoprotective; FDA-approved for erythropoietic protoporphyria (EPP).

Safety profile

Nausea, facial flushing, fatigue, spontaneous erections. Less sexual side effects than MT-2. Hyperpigmentation, mole changes. · FDA/EMA approved for EPP; nausea, headache mild; selective MC1R agonist; well-studied

Storage

Stability & handling

❄️Lyophilized (powder)2–8°Cstable for years
💉Reconstituted2–8°Cwithin 30 days
📈

Price tracking starts now.

Set an alert to get notified when this peptide drops.

Related pages

More on Melanotan-1

Stack & Compare

Frequently Researched Together

Research

Studies & key findings

  • FDA-approved as afamelanotide (Scenesse) for erythropoietic protoporphyria (EPP) — the first melanocortin agonist to receive regulatory approval anywhere in the world.
  • NEJM Phase 3 RCT (2015) demonstrated a significant increase in pain-free time in sunlight (duration doubled vs placebo) in EPP patients.

5 peer-reviewed sources cited — clinical, preclinical, and regulatory.

Read full research →
Failed to fetch